Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer

doi:10.3748/wjg.v32.i9.114200

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 9

This Article

(41)

(45)

(1)

(0)

(1)

(13)

(1)

(722)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Mar 7, 2026; 32(9): 114200
Published online Mar 7, 2026. doi: 10.3748/wjg.v32.i9.114200

Full Size Figure Download Figure

Figure 4 The performance of the nomograms in the validation cohort. A and B: Nomograms of overall survival (OS) and disease-free survival (DFS) based on the training cohort; C: Calibration curves for the nomogram of OS at 3, 5, 7 years in the validation cohort; D: Calibration curves for the nomogram of DFS at 3, 5, 7 years in the validation cohort; E: Receiver operating characteristic (ROC) curves for the nomogram of OS at 3, 5, 7 years in the validation cohort; F: ROC curves for the nomogram of DFS at 3, 5, 7 years in the validation cohort; G and H: Decision curve analyses (DCA) for the nomograms of OS (G) and DFS (H) at 3, 5, 7 years in the validation cohort. OS: Overall survival; DFS: Disease-free survival; AUC: Area under the curve; post-CEA: Postoperative carcinoembryonic antigen; AJCC: American Joint Committee on Cancer; CI: Confidence interval.

Citation: Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; 32(9): 114200
URL: https://www.wjgnet.com/1007-9327/full/v32/i9/114200.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i9.114200

Du FQ, Liu JL, Mai LD, Han XH, Song WJ, Yang D, Zhang QJ, Zhang R, Liu YL, Tong JX. Perioperative serum carcinoembryonic antigen: Powerful marker for prognostic prediction and adjuvant chemotherapy decision-making in patients with stage II and III colorectal cancer. World J Gastroenterol 2026; 32(9): 114200 [PMID: 41810442 DOI: 10.3748/wjg.v32.i9.114200]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.